Literature DB >> 2826590

Monoclonal antibody to human IgG Fc receptors. Cross-linking of receptors induces lysosomal enzyme release and superoxide generation by neutrophils.

H E Willis1, B Browder, A J Feister, T Mohanakumar, S Ruddy.   

Abstract

The monoclonal antibody KuFc79 binds to a determinant on the Fc receptors (Fc gamma R) of human leukocytes. We examined the biologic effects of the interaction of this antibody with Fc gamma R on human neutrophils (PMNL). The univalent Fab fragment of KuFc79 inhibits the formation of rosettes with IgG-sensitized sheep erythrocytes by as much as 91.7%. In other experiments in which PMNL were washed after exposure to Fab of KuFc79, phagocytosis of IgG-sensitized sheep erythrocytes was inhibited by 36%. Fab fragments of other mouse IgG2b monoclonal proteins did not have these effects. When PMNL are exposed to coverslips coated with univalent Fab fragments of this antibody, the Fc gamma R are removed from the surface of the PMNL. Under these conditions, rosetting could be inhibited by 85.4%. We examined cross-linking of receptor bound monoclonal antibody or its Fab fragment by either Protein A or F(ab')2 of an anti-mouse Ig. As much as 31.7% of beta-glucuronidase, a marker for lysosomal enzymes, is specifically released by cross-linking the Fc gamma R on PMNL. The generation of O2- is also induced by specifically cross-linking Fc gamma R with Fab and anti-Fab. The data constitute the first formal demonstration that cross-linking of Fc gamma R on PMNL leads to enzyme release and superoxide generation.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2826590

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  16 in total

Review 1.  Functions of the Fc receptors for immunoglobulin G.

Authors:  B K Flesch; J Neppert
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

Review 2.  Function and heterogeneity of human Fc receptors for immunoglobulin G.

Authors:  J C Unkeless
Journal:  J Clin Invest       Date:  1989-02       Impact factor: 14.808

3.  Fc gamma RII restriction fragment length polymorphism (RFLP): analysis in systemic lupus erythematosus and scleroderma and evidence of an alpha gene duplication.

Authors:  E C Jazwinska; C Olive; P M Hogarth; P A Gatenby; S W Serjeantson
Journal:  Clin Exp Immunol       Date:  1991-01       Impact factor: 4.330

4.  An abnormality of the gene that encodes neutrophil Fc receptor III in a patient with systemic lupus erythematosus.

Authors:  M R Clark; L Liu; S B Clarkson; P A Ory; I M Goldstein
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

5.  The polymorphic Fc gamma receptor II gene maps to human chromosome 1q.

Authors:  H O Grundy; G Peltz; K W Moore; M S Golbus; L G Jackson; R V Lebo
Journal:  Immunogenetics       Date:  1989       Impact factor: 2.846

6.  Impairment of neutrophil Fc gamma receptor mediated transmembrane signalling in active rheumatoid arthritis.

Authors:  N J Goulding; P M Guyre
Journal:  Ann Rheum Dis       Date:  1992-05       Impact factor: 19.103

7.  Recombinant soluble Fc gamma RII inhibits immune complex precipitation.

Authors:  A L Gavin; B D Wines; M S Powell; P M Hogarth
Journal:  Clin Exp Immunol       Date:  1995-12       Impact factor: 4.330

Review 8.  Functional capacity of Fc gamma receptor III (CD16) on human neutrophils.

Authors:  J C Edberg; J E Salmon; R P Kimberly
Journal:  Immunol Res       Date:  1992       Impact factor: 2.829

9.  A systematic study of neutrophil degranulation and respiratory burst in vitro by defined immune complexes.

Authors:  W Zhang; J Voice; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1995-09       Impact factor: 4.330

10.  Insoluble immune complex-stimulated neutrophil leukotriene B4 production is dependent on Fc gamma RII and Fc gamma RIII and independent of pertussis toxin-sensitive signal transduction pathways.

Authors:  E Crockett-Torabi; C W Smith; J R Kateley; R Patterson; P Tsai; J C Fantone
Journal:  Am J Pathol       Date:  1992-03       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.